Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -15.02% is 99% above its 3-year average of -2241.06%, near the high end of its 3-year range (-130288.89%–99.24%).
82.65% above its 12-month average of -86.58%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -239.24%.
GROSS MARGIN
-15.02%
GROSS MARGIN AVG TTM
-86.58%
GROSS MARGIN AVG 3Y
-2295.05%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+82.65%
CURRENT VS 3Y AVG
+99.35%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-136.30%
vs the sector median at left
CG Oncology Inc.
Market Cap
$5.61B
Gross Margin
-15.02%
TTM Avg
-86.58%
3Y Avg
-2295.05%
5Y Avg
N/A
Market Cap
$5.52B
Gross Margin
53.85%
TTM Avg
55.16%
3Y Avg
56.69%
5Y Avg
56.69%
Market Cap
$5.79B
Gross Margin
97.23%
TTM Avg
60.83%
3Y Avg
-170.72%
5Y Avg
-113.81%
Market Cap
$5.87B
Gross Margin
54.49%
TTM Avg
70.12%
3Y Avg
77.23%
5Y Avg
64.22%
Market Cap
$5.32B
Gross Margin
95.85%
TTM Avg
94.37%
3Y Avg
93.84%
5Y Avg
94.07%
Market Cap
$5.95B
Gross Margin
98.58%
TTM Avg
95.46%
3Y Avg
84.33%
5Y Avg
82.16%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.61B | -15.02% | -86.58% | -2295.05% | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 9.70% | 9.04% | 10.84% | 11.30% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 53.85% | 55.16% | 56.69% | 56.69% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | 97.23% | 60.83% | -170.72% | -113.81% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 54.49% | 70.12% | 77.23% | 64.22% |
| GRAIL Inc. (GRAL)vs › | $5.89B | -42.52% | -52.32% | -104.24% | -183.56% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 95.85% | 94.37% | 93.84% | 94.07% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 98.58% | 95.46% | 84.33% | 82.16% |
| Sotera Health Company (SHC)vs › | $5.20B | 54.72% | 55.10% | 55.18% | 55.10% |
Gross Margin
-15.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -239.24% |
| 2026-03-31 | -173.50% |
| 2025-12-31 | -25.50% |
| 2025-09-30 | 5.34% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | -52721.15% |
| 2024-12-31 | -5777.19% |
| 2024-09-30 | -45532.56% |
| 2024-06-30 | -16539.64% |
| 2024-03-31 | 99.24% |
| 2023-12-31 | -300.00% |
| 2023-09-30 | -130288.89% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -3942.27% |
| 2022-12-31 | 0.00% |
